— Research note —
BPC-157
Synthetic 15-residue peptide derived from a gastric juice protein fragment, investigated in preclinical models for tissue repair, angiogenesis, and gastrointestinal protection.
BPC-157, also referred to as Body Protection Compound-157 or PL 14736 in earlier nomenclature, is a synthetic 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV. The sequence was derived from a fragment of a larger protein identified in human gastric juice during work in the laboratory of Predrag Sikiric at the University of Zagreb, with foundational reports appearing from the early 1990s onward. Unlike many bioactive peptides, BPC-157 is reported to be stable in gastric acid, a property that has shaped much of the preclinical research design around the molecule.
The preclinical literature surrounding BPC-157 is unusually broad relative to the limited human clinical record. Investigators have examined the peptide in rodent models of tendon transection, muscle crush injury, segmental bone defects, colocutaneous and esophagogastric fistulas, inflammatory bowel disease analogs, traumatic brain injury, spinal cord compression, and various chemically induced gastric ulcer paradigms. Across these models, researchers have reported accelerated healing kinetics, reduced lesion area, and improved functional recovery relative to control conditions. Additional preclinical work has examined interactions with nitric oxide synthase inhibitors, dopaminergic and serotonergic systems, and growth factor expression in injured tissues.
Despite the breadth of animal data, controlled human clinical trials remain limited. Early-phase studies sponsored by the original developers examined intravenous and oral formulations in inflammatory bowel disease populations, but the compound has not progressed through a registrational program comparable to other peptide therapeutics, and no major regulatory approval exists. The scientific community continues to debate the translatability of the rodent findings, the heterogeneity of dosing routes and vehicles across studies, and the concentration of foundational work within a small number of research groups.
BPC-157 nevertheless remains a frequently cited reference compound in preclinical regenerative-medicine research and in academic investigations of gastric mucosal defense. Its accessibility, sequence stability, and reported activity across multiple injury models have sustained ongoing interest in mechanistic work, including studies of VEGFR2 signaling, focal adhesion kinase activation, and nitric oxide system modulation. The compound is supplied here strictly for laboratory research use and is not intended for human consumption.
Mechanism
The molecular mechanism of BPC-157 remains incompletely characterized, but preclinical investigations have converged on several signaling nodes. The most prominent line of evidence implicates the vascular endothelial growth factor receptor 2 (VEGFR2) pathway. In endothelial cell assays, exposure to BPC-157 has been reported to upregulate VEGFR2 expression and promote VEGFR2 internalization and downstream activation of the AKT and endothelial nitric oxide synthase axis, providing a candidate explanation for the angiogenic effects observed in tissue-repair models.
A second body of work emphasizes modulation of the nitric oxide system. Researchers have reported that BPC-157 counteracts the gastric and systemic effects of nitric oxide synthase inhibition by L-NAME and of excessive nitric oxide donation by L-arginine in rodent paradigms, suggesting a homeostatic interaction with NO signaling rather than direct agonism. Additional reports describe modulation of dopaminergic, serotonergic, and GABAergic systems in central nervous system injury models, upregulation of growth hormone receptor expression in tendon fibroblasts, and effects on focal adhesion kinase and paxillin in injured tissues. The integration of these signals into the observed repair phenotypes remains an active area of investigation.
Research history
The origins of BPC-157 trace to research at the University of Zagreb in the late 1980s and early 1990s, when investigators in the Sikiric laboratory identified a cytoprotective fraction of human gastric juice and progressively narrowed the active sequence to a 15-amino-acid peptide. Initial reports characterized the molecule in models of gastric and duodenal ulceration, where it was observed to attenuate lesion formation induced by alcohol, indomethacin, and stress paradigms. The peptide was subsequently designated PL 14736 during early industrial development.
Through the 1990s and 2000s, the Zagreb group and collaborators expanded the preclinical scope substantially. Reports appeared on tendon-to-bone healing after Achilles tendon transection in rats, on transected medial collateral ligaments, on muscle crush injury, on segmental bone defects, on colon anastomosis, and on chemically induced colitis. Investigators reported consistent acceleration of healing markers, neovascularization, and functional recovery. Parallel work examined central nervous system applications, including models of traumatic brain injury, spinal cord compression, and neurotoxicant exposure.
Early-phase human research conducted by Pliva and successor sponsors examined BPC-157 in inflammatory bowel disease in the early 2000s, but the program did not progress to large registrational trials, and contemporary human evidence remains thin. Mechanistic work intensified in the 2010s and 2020s, with multiple groups examining VEGFR2 internalization, nitric oxide system interactions, and downstream growth factor expression. Independent replication of the foundational injury-model findings outside the originating laboratories has been more limited than the volume of primary publications might suggest, a point frequently noted by reviewers. The compound nonetheless continues to attract preclinical interest, with new reports periodically extending its profile into additional injury, ischemia, and inflammation paradigms.
References
- Sikiric P, Seiwerth S, Rucman R, et al. 2018. Stable Gastric Pentadecapeptide BPC 157 as a Therapy in Preclinical and Clinical Studies. Curr Pharm Des. PMID: 29945549
- Chang CH, Tsai WC, Lin MS, et al. 2011. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. PMID: 21330616
- Sikiric P, Seiwerth S, Rucman R, et al. 2013. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. PMID: 24403878
- Hsieh MJ, Liu HT, Wang CN, et al. 2017. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). PMID: 27815573
- Krivic A, Anic T, Seiwerth S, et al. 2006. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. PMID: 16514657
- Veljaca M, Pavic Sladoljev D, Mildner B, et al. 2003. Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers. Gut.
- Sikiric P, Petek M, Rucman R, et al. 1993. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. PMID: 8298609
Do you have any questions about BPC-157?
Pick a path. The research assistant has the full literature context loaded.
Information presented in third-person scientific context. Research use only. Not medical advice; not for human consumption.